Eli Lilly vs Pfizer
Eli Lilly reported revenue of $65.2 billion in fiscal 2025, about the same as Pfizer's $62.6 billion in fiscal 2025. Eli Lilly's revenue grew 44.7% in its latest year, and Pfizer's fell 1.6%. Free cash flow was $9.0 billion at Eli Lilly and $9.1 billion at Pfizer.
Side by side
| Eli Lilly | Pfizer | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $65.2B | $62.6B |
| Revenue growth | 44.7% | −1.6% |
| Revenue growth a year, last 5 years | 21.6% | 8.5% |
| Gross margin | 83.0% | 74.3% |
| Operating margin | — | — |
| Net margin | 31.7% | 12.4% |
| Free cash flow | $9.0B | $9.1B |
| Free cash flow margin | 13.8% | 14.5% |
| Return on capital | 40.8% | 7.2% |
| Net debt to EBITDA | 1.2x | 3.2x |
| Dividends and buybacks | $9.5B | $9.8B |
| Change in diluted share count | −0.5% | 0.2% |
| Last close | $1,279.14 | $29.79 |
| P/E at the last close | 42.9× | 39.2× |
| Insider trades, last 12 months | sold $2.5 billion | bought $3.0 million, sold $134,661 |
| Piotroski F-score | 8 of 9 | 6 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Eli LillyPfizer
Operating margin
Percent of revenue
Eli LillyPfizer
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Eli LillyPfizer